Skip to content
Operating

Gain (Loss) on Sale of Assets and Asset Impairment Charges

Over 4 years (FY 2021 to FY 2025), Gain (Loss) on Sale of Assets and Asset Impairment Charges shows a downward trend with a -100.0% CAGR.

Analysis

StatementCash Flow Statement
SectionOperating
First reportedQ1 2013
Last reportedQ4 2025Feb 11, 2026
Metric ID: operating_gain_loss_on_sales_of_assets_and_asset_impairm_2fb394

Historical Data

5 years
 FY'21FY'22FY'23FY'24FY'25
Value$295.97M-$8.4M$71.19M$0$0
YoY Change-102.8%+947.5%-100.0%
Range-$8.4M$295.97M
CAGR-100.0%
Avg YoY Growth+248.2%
Median YoY Growth-100.0%

Frequently Asked Questions

What is Albemarle's gain (loss) on sale of assets and asset impairment charges?
Albemarle (ALB) reported gain (loss) on sale of assets and asset impairment charges of $0 in Q4 2025.
What is the long-term trend for Albemarle's gain (loss) on sale of assets and asset impairment charges?
Over 4 years (2021 to 2025), Albemarle's gain (loss) on sale of assets and asset impairment charges has grown at a -100.0% compound annual growth rate (CAGR), from $295.97M to $0.